Visão geral da empresa
A clinical stage biopharmaceutical entity, Phio Pharmaceuticals Corp., specializes in the development of immuno-oncology therapeutics within the United States market. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a domain characterized by high-risk research and development activities aimed at creating novel treatments for cancer and other diseases. With a market capitalization of $14.64M and a workforce comprising six employees, the organization maintains a very small operational footprint relative to typical public corporations. These valuation and employment figures indicate that the company is in an early-stage growth phase, where limited resources are concentrated on advancing specific asset pipelines rather than scaling commercial operations or generating significant sales volume. The absence of substantial revenue generation at this stage is consistent with the lifecycle of a clinical stage entity focused on transitioning candidates into later-stage trials.
Saúde financeira
The company reports no annual revenue and a net income of $-8,698,000 over the trailing twelve months, while EBITDA stands at $-9,217,000. The complete absence of revenue combined with significant negative net income and EBITDA reveals a cost structure dominated by research and development expenses necessary to advance clinical programs like PH-762 and PH-894, rather than operational overhead associated with sales. Free cash flow is reported at $-5,056,500, which signifies that the company is currently burning through its capital reserves to fund its scientific endeavors and has no cash generation from operations to support its activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability and that its financial performance is entirely driven by non-operating factors or the lack of commercial sales. Despite the negative income, the company holds $21.03M in cash against $0 in debt, creating a capital position that is highly conservative and devoid of financial leverage. The debt-to-equity ratio is not applicable due to the lack of debt and equity dynamics typical of pre-revenue firms. Furthermore, the current ratio of 16.03 suggests an exceptionally strong short-term liquidity position, implying that the company possesses more than enough current assets to cover its immediate liabilities. Return on Equity is -69.9% and Return on Assets is -42.3%, metrics that reflect the dilutive nature of the company's current financial state and the heavy investment required to build value before any return to shareholders can be realized.
Avaliação de valorização
The trailing twelve-month P/E ratio is not applicable given the lack of earnings, while the forward P/E is listed as -2.03, a metric that typically does not exist for unprofitable companies but is calculated here based on negative earnings and market data. The discrepancy between these metrics highlights that standard profitability-based valuation models are not suitable for Phio Pharmaceuticals, as they rely on negative earnings figures that distort traditional analysis. The price-to-book ratio is 0.73, suggesting that the market values the company at less than its net asset value, which is common for biotechnology firms with significant intangible assets like intellectual property that are not fully captured on the balance sheet. The price-to-sales ratio is not applicable due to zero revenue, and the EV/EBITDA stands at 0.69, offering an alternative perspective that values the firm based on its enterprise value relative to its negative earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $4.19 and a 52-week low of $0.81, establishing a wide trading range that reflects the high volatility inherent in small-cap biotechnology stocks. The beta value is 0.91, indicating that the stock's price volatility is roughly equal to the broader market, meaning it does not exhibit extreme sensitivity to market-wide movements despite its small market cap.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not applicable, as the company has not yet generated commercial revenue or consistent positive earnings to calculate growth rates. The absence of positive earnings growth means that the company is not in a stage where profitability is expanding, but rather where it is focusing on reducing losses through successful clinical trial outcomes and eventual product launch. Phio Pharmaceuticals is not a dividend payer, as evidenced by a dividend yield of not applicable and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings, or rather its remaining cash reserves, directly back into research and development to advance its immuno-oncology pipeline rather than distributing cash to shareholders. The overall growth and income profile is defined by a lack of current financial returns, where the primary metric for success is the progression of clinical assets rather than financial statement improvements or dividend distributions to investors.